Exagen inc. announces clinical study support for horizon therapeutics plc

Exagen inc. announced clinical study support for horizon therapeutics plc to measure methotrexate polyglutamates (mtxpgs), the active metabolites of methotrexate (mtx) in the mirror randomized controlled trial (rct) study. this study, methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase, will enroll approximately 135 subjects to evaluate the use of methotrexate as an immunomodulator to meaningfully attenuate an immune response to pegloticase in adults living with uncontrolled gout. many biologics have an improved response rate when they are administered together with methotrexate, which reduces the formation of anti-drug antibodies.
XGN Ratings Summary
XGN Quant Ranking